<DOC>
	<DOCNO>NCT02753712</DOCNO>
	<brief_summary>The purpose study demonstrate improvement peripheral airway resistance ( R5-R20 ) baseline fluticasone/formoterol breath actuate inhaler ( BAI ) .</brief_summary>
	<brief_title>A Study Evaluate Effect Fluticasone/Formoterol Breath Actuated Inhaler ( BAI ) Relvar® Ellipta® DPI Ventilation Heterogeneity Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Inclusion Criteria subject Seretide Accuhaler 250/50 µg screening : 1 . Male female subject ≥18 year old . 2 . Adequate contraception 3 . Documented clinical history asthma ≥6 month prior screen visit 4 . Using Seretide Accuhaler stable dose 250/50 μg BID screen ≥ 8 week . 5. uncontrolled asthma define Asthma Control Questionnaire ( ACQ6 ) score ≥ 1.0 6 . R5R20 ≥ 0.10 kPa/L/s measure impulse oscillometry screen visit . 7 . Historical evidence ( within 24 month ) eosinophilic airways disease evidence sputum eosinophil count ≥ 3 % and/or FeNO 35 ppb . Inclusion criterion subject equivalent /higher dose ICSLABAs high dose Seretide screening : 1 . Male female subject ≥18 year old . 2 . Adequate contraception 3 . Documented clinical history asthma ≥6 month prior screen visit 4 . R5R20 ≥0.07 kPa/L/s measure impulse oscillometry screen visit . 5 . Historical evidence ( within past 24 month ) eosinophilic airways disease , evidence sputum eosinophil count ≥3 % and/or FeNo ≥35 ppb . Exclusion Criteria subject : 1 . Any severe chronic respiratory disease asthma . 2 . Subject smoke history ≥10 `` pack year '' ( i.e. , least 1 pack 20 cigarettes/day 10 year 10 packs/day 1 year , etc . ) 3 . Current smoke history within 12 month prior screen visit 4 . Near fatal lifethreatening ( include intubation ) asthma within past year . 5 . Known history systemic ( injectable oral ) corticosteroid medication within 1 month visit 1 . 6 . Evidence clinically unstable disease determine medical history physical examination , investigator 's opinion , precludes entry study . 'Clinically unstable ' defined disease , opinion Investigator , would put subject risk study participation , would affect outcome study . 7 . In investigator 's opinion clinically significant upper low respiratory infection within 4 week prior visit 1 . 8 . Current evidence know history alcohol and/or substance abuse within 12 month prior screen visit . 9 . Subject take βblocking agent , tricyclic antidepressant , monoamine oxidase inhibitor , astemizole , quinidine type antiarrhythmic , potent CYP 3A4 inhibitor ketoconazole within 1 week prior screen visit . 10 . Current use bronchodilator / antiinflammatory agent specify protocol . 11 . Known suspected sensitivity study drug excipients . 12 . Participation clinical drug study within 30 day screen visit . 13 . Current participation clinical study . Exclusion Criteria subset subject undergo ORMRI HDCT 1 . Contraindication MRI scanning ( assessed local MRI safety questionnaire ) , include , limited : presence nonMRI compatible artificial heart valve , hydrocephalus shunt , intracranial aneurysm clip , joint replacement metal implant , pacemaker cardiac rhythm management device , claustrophobia , history metal eye , presence shrapnel war injury , calliper brace , denture , dental plate hear aid include metal remove , history epilepsy blackout , ear implant , piercings remove , intrauterine contraceptive device coil . 2 . Inability stay supine position duration scan procedure 3 . Obesity ( body weight &gt; 140kg ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Small airway disease</keyword>
	<keyword>asthma</keyword>
</DOC>